MGMT and neoplasm: At six-month follow-up, tumor progression distribution revealed 11 IDH mutant and 13 IDH wildtype cases in the MGMT methylated group (total 24 progressions), compared to 11 IDH mutant and 17 IDH wildtype cases in the MGMT unmethylated group (total 28 progressions).